| Email |
seshlem@jhmi.edu |
| Phone |
(410) 614-4734 |
|
|
Susan H. Eshleman, M.D., Ph.D.
Primary Appointment in Pathology
Member, Graduate Program in Cellular and Molecular Medicine; Member, Graduate Program in Pathobiology
The HIV-1 viruses in an infected individual are genetically diverse and evolve at a rapid rate in response to selective pressures. My laboratory studies HIV-1 diversity and its impact on HIV-1 infection and viral fitness. Major areas of interest of the laboratory include HIV-1 mother-to-child transmission and HIV-1 drug resistance. We are also involved in both national and international clinical trials of HIV-1 treatment and prevention.
Publications
Eshleman SH, Becker-Pergola G, Deseyve M, Guay LA, Mracna M, Fleming T, Cunningham S, Musoke P, Mmiro F, and Jackson JB. Impact of human immunodeficiency type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for Prevention Trials 012 Study). J Infect Dis. (2001) 184:914-917.
Eshleman SH, Guay LA, Fleming T, Mwatha A, Mracna M, Becker-Pergola G, Musoke P, Mmiro F, and Jackson JB. Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012). J AIDS (2002) 31:327-330.
Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, Mmiro F, and Jackson JB. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single dose NVP prophylaxis: HIVNET 012. AIDS Res Human Retroviruses (2004) 20:595-597.
Shi C, Eshleman SH, Jones D, Fukishima N, Hua L, Parker AR, Yeo CJ, Hruban RH, Goggins MG, and Eshleman JR. LigAmp: Sensitive detection of single nucleotide differences. Nature Methods (2004) 1:141-147. |
|
| Email |
bjackso@jhmi.edu |
| Phone |
(410) 955-9790 |
|
|
J. Brooks Jackson, M.D., M.B.A.
Baxley Professor and Director of Pathology
Member, Graduate Program in Pathobiology
My research is focused on the clinical application of several qualitative and quantitative HIV-1 detection assays for the purpose of 1) studying perinatal, sexual, and transfusion-associated HIV transmission and 2) monitoring HIV infection pre and post antiretroviral therapy. Laboratory assays for the detection and quantitation of HIV include Western blot analysis, HIV culture, p24 antigen levels, and quantitation of HIV DNA and RNA by PCR. Drug susceptibility and neutralizing antibody assays are also employed. These methods are extremely helpful in evaluating new antiviral drugs, understanding modes and frequency of HIV transmission, and understanding the pathogenesis of HIV-1 infection. Trials using HIV immune globulin, AZT, and nevirapine to prevent HIV vertical transmission in Uganda are also underway.
Publications
Jackson JB, Barnett S, Piwowar-Manning E, Apuzzo L, Raines, C, Hendrix C, Hamzeh F, Gallant J. A Phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk. AIDS 2003; 17:547-553.
Piwowar-Manning E, Henderson TA, Brisbin L, Jackson JB. A modified ultrasensitive assay to detect quantified HIV-1 RNA levels less than 50 copies/ml. Am J Clin Pathol 2003;120:268-270.
Jackson JB, Musoke P, Fleming T, Guay L, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Emel L, Duefield C, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 months follow-up of the HIVNET 012 randomised trial. Lancet 2003;362:859-868.
Jackson JB, Piwowar-Manning E, Johnson-Lewis L, Bassett R, Demeter LM, Brambilla D. Comparison of 1.0 and 1.5 version ultrasensitive AMPLICOR HIV-1 MONITOR test in subjects with low viral load. J Clin Microbiol 2004;42:2774-2776. |
|
| Email |
kking@jhmi.edu |
| Phone |
(410) 955-6583 |
|
|
Karen E. King, M.D.
Primary Appointment in Pathology; Secondary Appointment in Oncology
My research is focused in two areas: 1) the problem of alloimmunization due to either multiple transfusions or fetal maternal incompatibility and 2) novel indications for apheresis. My interests involve the clinical complications related to red cell alloimmunization, specifically delayed hemolytic transfusion reactions and the phenomenon of bystander hemolysis. I am particularly interested in the transfusion related issues which complicate the course of patients with sickle cell disease, especially those issues due to alloimmunization and multiple transfusions. In the Hemapheresis and Transfusion Support (HATS) service, our resources include apheresis technology and staff skilled in performing therapeutic and donor apheresis. We also provide outpatient donor and transfusion services. Our platelet coordinators manage platelet transfusion therapy for multitransfused, refractory patients. The translational aspects of this service facilitate close interactions with research and clinical investigators in many fields. Currently, one very successful collaboration involves the development of clinical protocols for kidney transplantation across HLA and ABO barriers. We are also involved in clinical trials of novel apheresis technologies and we are participating in the Transfusion Medicine/Hemostasis Clinical Trial Network sponsored by NHLBI.
Publications
King KE, Shirey RS, Lankiewicz MW, Young-Ramsaran J, Ness PM. Delayed hemolytic transfusion reactions in sickle cell disease: simultaneous destruction of recipients' red cells. Transfusion 1997;37:376-381.
Ness PM, Shirey RS, Weinstein MH, King KE. An animal model for delayed hemolytic transfusion reactions. Transfusion Medicine Reviews 2001;15:305-317.
Shirey RS, Boyd JA, Parwani AV, Tanz WS, Ness PM, King KE. Prophylactic antigen-matched donor blood for patients with warm autoantibodies: an algorithm for transfusion management. Transfusion 2002;42:1435-1441.
King KE, Shirey RS, Thoman SK, Bensen-Kennedy D, Tanz WS, Ness PM. Universal leukoreduction decreases the incidence of febrile non-hemolytic transfusion reactions to RBCs. Transfusion 2004;44:25-29.
Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, Shirey RS, Simpkins CE, Montgomery RA. Plasmapheresis, CMV hyperimmune globulin , and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004;4:1315-1322. |
|
| Email |
wsavage1@jhmi.edu |
| Phone |
(410) 955-6583 |
|
|
William Savage, M.D.
Primary Appointment in Pathology; Secondary Appointment in Pediatrics, division of Pediatric Hematology
My overall interest is in transfusion medicine and pediatric hematology clinical and translational research. My research is focused on discovery and validation of biomarkers that track organ damage in people with sickle cell disease, many of whom receive chronic red blood cell transfusions. We use both proteomic and candidate-protein based approaches. I also analyze clinical datasets to identify which transfusion-related factors can minimize the morbidity of chronic red cell transfusion.
Publications
Savage WJ, Barber JP, Mukhina GL, Hu R, Chen G, Matsui W, Thoburn C, Hess AD, Cheng L, Jones RJ, Brodsky RA. Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNH. Exp Hematol. 2009 Jan;37(1):42-51. Epub 2008 Nov 14.
Savage WJ, DeRusso PA, Resar LM, Chen AR, Higman MA, Loeb DM, Jones RJ, Brodsky RA. Treatment of hepatitis-associated aplastic anemia with high-dose cyclophosphamide. Pediatr Blood Cancer. 2007 Dec;49(7):947-51.
Savage WJ, Kickler TS, Takemoto CM. Acquired coagulation factor inhibitors in children after topical bovine thrombin exposure.Pediatr Blood Cancer. 2007 Dec;49(7):1025-9.
Savage WJ, Bleesing JJ, Douek D, Brown MR, Linton GM, Malech HL, Horwitz ME. Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism. Bone Marrow Transplant. 2001 Sep;28(5):463-71. |
|
| Email |
hshan@jhmi.edu |
| Phone |
(410) 614-4246 |
|
|
Hua Shan, M.D., Ph.D.
Primary Appointment in Pathology
The risk of transfusion transmitted infections (TTI, including HIV, HBV and HCV) has decreased significantly in recent years in developed countries. Unfortunately, many developing countries still have TTI risk levels that are significantly higher than developed countries. My recent works have been focused on developing collaborative research programs with international blood centers with the purpose of identifying ways to improve international blood safety.
Donor follow-up case controlled studies have been carried out in blood centers in Beijing and Urumqi, China to identify risk factors associated with donor HIV and HCV infections. The reported common risk factors among donors in the United States include a history of injection drug abuse (IDU) and a history of blood transfusion before 1990. Our preliminary findings from Chinese blood centers revealed the history of blood (whole blood or plasma) donation prior to 1995 as a leading risk factor for both HIV and HCV infections. The current donor deferral criteria used at Chinese blood centers does not defer donors with donation history prior to 1995. Based on our findings, we are proposing changes to the existing donor deferral criteria to more effectively prevent high-risk donors from entering the donor pool.
We are conducting a multi-blood center study using the nucleic acid based donor test (NAT) to evaluate the prevalence, incidence, and the residual risk level of HIV and HCV in China. We also recently completed a knowledge, attitude and practice (KAP) survey in Urumqi, China to gain better understanding of potential donors in order to develop more effective donor recruitment methods. We are also currently conducting a study in Beijing searching for inexpensive HCV confirmatory methods (instead of the RIBA test, as used in developed countries) that can be used in resource-poor countries.
Publications
Hua Shan and Ping Zhang. Viral Attack On Blood Collection: The Experience From Beijing During The SARS Epidemic. 2004. Transfusion; 44: 467-469
Lynn Mattis, Hua Shan , Eric Powell, Sue Shirey and Maria Oliva-Hemker. Life threatening ceftriaxone-induced hemolytic anemia in a child with Crohn's disease. Clinical Pediatrics 2004;43:175-178
SARS epidemiological survey among blood donors, Guojing Gao, Yan Qiu, Ping Zhang, Hua Shan et al, Chinese Journal of Blood Transfusion, 2003, Vol.16. No. 4 (223-226)
Shan H, Piwowar-Manning E, Thompson RE, Brooks Jackson J. HIV-1 plasma RNA level and CD4 cell count in a large urban HIV-1-infected patient population from 1997 to 2000. Int J STD AIDS. 2003 Nov;14(11):740-4.
Hua Shan, Jing-Xing Wang, Fu-Rong Ren, Yuan-Zhi Zhang, Hai-Yan Zhao, Guo-Jing Gao, Yang Ji and Paul M Ness. Blood Banking in China. The Lancet. 2002 Vol 360. No. 9347:1770-1775 |
|
|
